A SYSTEMATIC REVIEW OF HEPATITIS VIRUS REVIEW STUDIES: A CASE OF HEALTH ECONOMIC EVALUATION ANALYSIS
DOI:
https://doi.org/10.22159/ijpps.2017v9i5.17295Keywords:
Economic analysis, Economic evaluation, Hepatitis, Literature review, Systematic review, ReviewAbstract
Objective: Systematic reviews of economic analysis are necessary for assessing reports and making a decision. A systematic review of systematic reviews is mean of summarizing the current evidence across specialties of the same or very similar intervention, to provide a synthesis treatment effect. The aim of this study was to explore and to assess the quality of systematic reviews conducted hepatitis economic evaluation.
Methods: This study was designed as a systematic review following the AMSTAR guideline through Medline, Cochrane, and Science Direct databases. It was scoped in publication period of 2001 and 2016 in international journals. The quality assessment of the included studies was based on AMSTAR checklist. Two authors did the appreciation independently and all the different results were solved by discussion to give the conclusion.
Results: 851 publications found, only 25 studies of those met the inclusion criteria. These studies consisted of 5 studies for vaccination and 20 for non-vaccination. There were only 16% (n=4) based on PRISMA guideline; and twenty-one studies (64%) were not showing about the method of the systematic review or not based on any guideline. Only three articles has published in 2016 with a high standard.
Conclusion: According to the results of the appraisal AMSTAR checklist, this review shows clearly the current situation and an urgent need for an increase of quality of hepatitis virus review studies based on health economic evaluation.
Downloads
References
De Soarez PC, Sartori AM, Santos A, Itria A, Novaes HM, Martelli CM. Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil. Cad Saude Publica 2012;28:211-28.
Bowater RJ, Stirling SA, Lilford RJ. Is antibiotic prophylaxis in surgery a generally effective intervention? Testing a generic hypothesis over a set of meta-analyses. Ann Surg 2009;249:551-6.
Bowater RJ, Abdelmalik SM, Lilford RJ. Efficacy of adjuvant chemotherapy after surgery when considered overall cancer types: a synthesis of meta-analyses. Ann Surg Oncol 2012; 19:3343-50.
Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol 2011;11:15.
Aggarwal R, Goel A. Hepatitis A. Epidemiology in resource-poor countries. Curr Opin Infect Dis 2015;28:488-96.
Pham B, Duval B, De Serres G, Gilca V, Tricco AC, Ochnio J, et al. Seroprevalence of hepatitis an infection in a low endemicity country: a systematic review. BMC Infect Dis 2005;5:56.
Anisyah Achmad RAF, Mustofa, Ayu Lestari Prihadi. The incidence of liver fibrosis based on non-invasive markers and hepatotoxic drug used in hepatitis B patients. Asian J Pharm Clin Res 2014;7:287-90.
Govindarao Kamala SV, K Naga Valli. Development and validation of rp-hplc method for simultaneous estimation of lamivudine and zidovudine in bulk. Int J Curr Pharm Res 2016;8:28-33.
Layek B, Lipp L, Singh J. APC targeted micelle for enhanced intradermal delivery of hepatitis B DNA vaccine. J Controlled Release 2015;207:143-53.
Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, P TK, et al. Cost-effectiveness analysis of alternative antiviral strategies for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis b in the united kingdom. Value Health 2015;18:800-9.
Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, et al. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Hum Vaccin Immunother 2014;10:2983-91.
Luhnen M, Waffenschmidt S, Gerber-Grote A, Hanke G. Health economic evaluations of sofosbuvir for the treatment of chronic hepatitis c: a systematic review. Appl Health Econ Health Policy 2016;14:527-43.
Llewellyn A, Faria R, Woods B, Simmonds M, Lomas J, Woolacott N, et al. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. Pharmacoeconomics 2016;34:981-92.
Wohl BM, Smith AAA, Jensen BEB, Zelikin AN. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation. J Controlled Release 2014;196:197-207.
Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, et al. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther 2016;44:620-8.
Adlhoch C, Avellon A, Baylis SA, Ciccaglione AR, Couturier E, de Sousa R, et al. Hepatitis E virus: assessment of the epidemiological situation in humans in Europe, 2014/15. J Clin Virol 2016;82:9-16.
Keya Chakrabarti KB, Karthik Rao N, Navin Patil, Avinash A, Talha Ahmed, George Varghese, et al. A study to assess the clinical and biochemical profile of patients diagnosed with hepatitis E in a large teaching hospital of southern india. Asian J Pharm Clin Res 2016;9:84-9.
Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer 2008;98:1166-75.
Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860-9.
Luyten J, Beutels P. Costing infectious disease outbreaks for economic evaluation: a review for hepatitis A. Pharmacoeconomics 2009;27:379-89.
Buti M, Oyaguez I, Lozano V, Casado MA. Cost-effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics 2013;31:63-75.
John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M. Cost-effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review. Pharmacoeconomics 2012;30:1015-34.
Geue C, Wu O, Xin Y, Heggie R, Hutchinson S, Martin NK, et al. Cost-Effectiveness of HBV and HCV screening strategies--a systematic review of existing modelling techniques. PLoS One 2015;10:e0145022.
Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013;13:181.
Ruggeri M. Hepatocellular carcinoma: cost-effectiveness of screening. A systematic review. J Risk Management and Healthcare Policy 2012;5:49-54.
Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Papastergiou V, Thalassinos E, et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: a systematic review and economic evaluation. J Viral Hepat 2016;23:139-49.
Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, et al. Cost-effectiveness analyses of hepatitis a vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 2008;26:17-32.
Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 2001;10:751-74.
Malewezi B, Omer SB, Mwagomba B, Araru T. Protecting health workers from nosocomial hepatitis B infections: a review of strategies and challenges for implementation of Hepatitis B vaccination among health workers in Sub-Saharan Africa. J Epidemiol Global Health 2016;6:229-41.
Rich JD, Ching CG, Lally MA, Gaitanis MM, Schwartzapfel B, Charuvastra A, et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 2003;114:316-8.
Trung Quang Vo AR. A literature review of health economics evaluation: a case of vaccination on systematic review analysis. J Appl Pharm Sci 2016;6:124-30.
Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 2015;151:27-40.
Ekeland AG, Bowes A, Flottorp S. Effectiveness of telemedicine: a systematic review of reviews. Int J Med Inform 2010;79:736-71.
Shea B DC, Moher D. Assessing the quality of reports of systematic reviews: the QUOROM statement compared to other tools. In: Systematic Reviews in Health Care: Meta-analysis in context. Edited by: Egger M, Smith GD, Altman DG. London: BMJ books 2001;7:122-39.
Shea BJ GJ, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:10.
Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
Oxman AD. Checklists for review articles. Br Med J 1994; 309:648-51.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
Crowe M, Sheppard L. A review of critical appraisal tools show they lack rigor: alternative tool structure is proposed. J Clin Epidemiol 2011;64:79-89.
Shea BJ HC, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, Henry DA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009;62:1013-20.
Sharif MO, Janjua-Sharif FN, Ali H, Ahmed F. Systematic reviews explained: AMSTAR-how to tell the good from the bad and the ugly. Oral Health Dent Manag 2013;12:9-16.
Sequeira-Byron P, Fedorowicz Z, Jagannath VA, Sharif MO. An AMSTAR assessment of the methodological quality of systematic reviews of oral healthcare interventions published in the Journal of Applied Oral Science (JAOS). J Appl Oral Sci 2011;19:440-7.
Faggion CM Jr. Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor. BMC Med Res Methodol 2015;15:63.
La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, et al. Economic evaluation of HBV vaccination: a systematic review of recent publications (2000-2013). Hum Vaccines Immunother 2016;12:2299-31.
Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 2009;8:907-20.
Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: a systematic review and economic evaluation. Health Technol Assessment 2015;19:1-409.
Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assessment 2009;13:1-172.
Sun X, Qin WX, Li YP, Jiang XH. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of the economic evidence. J Gastroenterol Hepatol 2007;22:1369-77.
Takeda A, Jones J, Shepherd J, Davidson P, Price A. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B. J Viral Hepat 2007;14:75-88.
Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assessment 2006;10:iii-iv, xi-xiv, 1-183.
Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis 2015;15:19.
San Miguel R, Gimeno-Ballester V, Mar J. Cost-effectiveness of protease inhibitor-based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoeconomics Outcomes Res 2014;14:387-402.
Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: a systematic review and economic evaluation. J Viral Hepat 2011;18:e381-93.
Hartwell D, Jones J, Baxter L, Shepherd J. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assessment 2011;15:i-xii, 1-210.
Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assessment 2007;11:1-205.
Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alpha-2a and-2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assessment 2004;8:iii-iv, 1-125.
Shepherd J, Brodin HF, Cave CB, Waugh NR, Price A, Gabbay J. Clinical and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005;21:47-54.
Published
How to Cite
Issue
Section
